Main Content

MCRTC Leadership

marshall_gailen-wc.jpgGailen D. Marshall, Jr., MD PhD
Executive Director
Dr. Marshall is the R. Faser Triplett Chair of Allergy and Immunology, Professor of Medicine, Pediatrics, Pathology, Population Health Sciences, Vice Chair for Research in the Department of Medicine and Medical Director for the Clinical Research Support Program (CRSP) and Clinical Research and Trials Units (CRTU) at UMMC. He has a national and international reputation in research investigating the mechanisms of excess psychological stress on immune dysfunction leading to various allergic and inflammatory diseases, particularly asthma. He has a 20+ year history of service as principal investigator for various industry sponsored and NIH-funded clinical trials. He also serves as the Translational Science Track Director for UMMC's Master of Science in Clinical Investigation degree program. He has served as major professor for three MD/PhD students and one PhD student in immunology and as mentor for four PhD and 19 MD postdoctoral fellows pursuing various research and quality projects in allergy and immunology. He has authored more than 250 peer reviewed manuscripts, reviews and book chapters.
Portrait of Leslie MusshafenLeslie A. Musshafen, MBA, CRA, CPRA
Interim Administrative Director
Leslie has more than 10 years of research administration experience supporting both pre- and post-award activities. Her experience includes the submission and management of several, multi-million dollar awards and contracts. Leslie is a Certified Research Administration (CRA) as well as a Certified Preaward Research Administration (CPRA) – the gold standard for those within the industry – and is also a member of the National Council of University Research Administrators. In her current role as Executive Director of Research at UMMC, she oversees all of the service offices within the research mission and works with leadership on strategic initiatives,  including the creation of the Clinical Research Support Program and funding and constructions of the Clinical Research and Trials Unit due to open in 2019.